• Neuronetics Inc STIM.OQ reported a quarterly adjusted loss of 44 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -33 cents. The mean expectation of four analysts for the quarter was for a loss of 23 cents per share. Wall Street expected results to range from -26 cents to -20 cents per share.

• Revenue rose 3.6% to $18.53 million from a year ago; analysts expected $19.13 million.

• Neuronetics Inc's reported EPS for the quarter was a loss of 44 cents​.

• The company reported a quarterly loss of $13.34 million.

• Neuronetics Inc shares had risen by 44.8% this quarter and lost 62.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

Wall Street's median 12-month price target for Neuronetics Inc is 3.00

This summary was machine generated from LSEG data November 12 at 03:29 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)